Tag Archives: treatments

Guest Post for IBS Awareness Month: Navigating the UK National Health Service for Irritable Bowel Syndrome (IBS)

IBS Impact is pleased to welcome a guest blogger this week for IBS Awareness Month.  Julie Thompson, RD, known on social media as Jules_GastroRD, is a UK state registered dietitian specializing in IBS and other gastrointestinal conditions. She runs the Calm Gut Clinic in Lancashire, is an advisor to the IBS Network, the UK’s national …

Continue reading

NICE in the United Kingdom Gives Positive Recommendation for Eluxadoline (Truberzi) for IBS-D

Today, via the social media of the IBS Network, the U.K. charity for irritable bowel syndrome, IBS Impact received the following linked press release from Allergan, the pharmaceutical company for eluxadoline, which is known in the U.K. and throughout the European Union by the brand name Truberzi. This is the same medication which is known …

Continue reading

U.S. Food and Drug Administration Issues Drug Safety Communication for IBS-D Medication Eluxadoline (Viberzi), March 2017

Today, March 15, 2017, IBS Impact learned via IFFGD social media that the U.S. Food and Drug Administration (FDA) issued a drug safety communication for eluxadoline (also known by the brand name Viberzi), currently used in treating irritable bowel syndrome with diarrhea in adults, 18 and older, both men and women. This warning applies specifically …

Continue reading

Interactive Infographic on Evidence-Based Treatments for Irritable Bowel Syndrome (IBS)

IBS Impact is primarily an awareness, advocacy and news blog by people with IBS and does not recommend specific treatments, as experiences of individuals. with IBS vary widely, and those decisions are appropriately made in consultation with one’s health care providers. However, the following interactive infographic from the BMJ (formerly the British Medical Journal) is …

Continue reading

U.S. Food and Drug Administration Approves Eluxadoline and Rifaximin for IBS with Diarrhea

Earlier this week, on May 27, 2015, the U.S. Food and Drug Administration approved two new medications, eluxadoline (to be known by the brand name Viberzi) and rifaximin (known by the brand name Xifaxan)  for use in treating irritable bowel syndrome with diarrhea in adults, 18 and older, both men and women. Both medications have …

Continue reading

Clinical Trial: Assessing Cognitive Behavioral Therapy in Irritable Bowel Syndrome University of Southampton, UK, 2015

The University of Southampton, in collaboration with Kings College, London, has an ongoing multi-center clinical trial begun in 2013 and expected to be published in 2018 comparing the clinical and cost effectiveness of therapist cognitive behavioral therapy and lower intensity web-based cognitive behavioral therapy for people with refractory irritable bowel syndrome (IBS). A total of …

Continue reading

NICE Guidelines in the United Kingdom for Adult Irritable Bowel Syndrome (IBS) Updated for 2015

Last month, February 2015, the National Institute for Health and Care Excellence, formerly the National Institute for Clinical Excellence and still widely known by its original acronym NICE, released revised guidelines for the diagnosis and treatment of adults with irritable bowel syndrome (IBS) in the United Kingdom. NICE’s stated goal is to provide evidence-based information …

Continue reading

Book Review: The Gut Solution for Parents with Children Who Have Recurrent Abdominal Pain and Irritable Bowel Syndrome

Because most educational materials, research studies and other resources related to irritable bowel syndrome are focused on adults, readers may not be aware that children and adolescents can also develop IBS. A subset of these young people may have a parent or other genetic relatives who also have IBS or a commonly overlapping chronic condition, …

Continue reading

Irritable Bowel Syndrome (IBS) and the Myth of a Cure

One can’t run an IBS website, forum or active social media account without sooner or later encountering all sorts of claims about a cure for IBS. Vigilant site owners and moderators who wish to do so can filter out many blatant offenders, but the same themes recur in forum postings, in the spam mail to …

Continue reading

UNC 2014 “Expert Update on Treatment of Functional GI Disorders” Patient Symposium Live and Online June 22-23, 2014

The University of North Carolina Center for Functional GI and Motility Disorders has announced that its 2014 Patient Symposium will take place at the Marriott Metro Center in Washington, DC on June 22-23, 2014. This event, scheduled to immediately precede IFFGD/DHA Advocacy Day 2014, is geared to people with functional GI disorders and families and  …

Continue reading